Cardiac transplantation in New Zealand: Eight years experience

New Zealand Medical Journal

Volumn 110, Issue 1042, 1997, Pages 139-142

  Lund, M ^a   Ellis, C J ^a   Coverdale, H A ^a   Agnew, T M ^a   Haydock, D A ^a   Middleton, N G ^a   Whitfield, C J ^a   Whitlock, R M L ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DILTIAZEM; IMMUNOSUPPRESSIVE AGENT; PRAVASTATIN; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEW ZEALAND; SURVIVAL;

ACTUARIAL ANALYSIS; ADULT; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PATIENT SELECTION;

EID: 0030988270     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Agnew TM, Coverdale HA, Graham KJ, et al. Cardiac transplantation in New Zealand: an initial report. NZ Med J 1989; 102: 634-7.
2. Hosenpud JD, Novick RJ, Breen TJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Twelfth official report - 1995. J Heart Lung Trans 1995; 14: 805-15.
3. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1993; 88: 2941-52.
4. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low dose amiodarone in severe congestive heart failure. Grupo do Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-8.
5. Sing SN, Fletcher RD, Fisher Susan G, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.
6. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl. VI): VI94-101.
7. Spratt P, Esmore D, Baron D, et al. Effectiveness of minimal dosage cyclosporin in limiting toxicity and rejection. J Heart Transplant 1986; 5: 8-12.
8. Brockmoller J, Neumayer HH, Wagner K, et al. Pharmacokinetic interactions between cyclosporin and diltiazem Eur J Clin Pharmacol 1990; 38: 237-42
9. Drexler H, Schroeder JS. Unusual forms of ischaemic heart disease. Curr Opin Cardiol 1994; Jul 9, (4):457-64.
10. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med 1993; 328: 164-70.
11. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
12. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1564-75.
13. Australian and New Zealand Cardiothoracic Organ Transplant Registry. Fifth Report. February 1984 - December 1985.
14. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Dis 1981; 34: 585-97.
15. O'Connell JB, Bourge RC, Costanzo-Nordin Maria R, et al. Cardiac transplantation: recipient selection, donor procurement, and medical follow-up. Circulation 1992; 86: 1061-79.